Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Response Evaluation Criteria in Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT04394975
What this trial is testing

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Who this might be right for
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
Shanghai Junshi Bioscience Co., Ltd. 421
Not applicableUnknownNCT03616951
What this trial is testing

Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

Who this might be right for
Renal Neoplasm With MetastasisResponse Evaluation Criteria in Solid Tumors
University of Aarhus 60
Large-scale testing (Phase 3)Study completedNCT03665441
What this trial is testing

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

Who this might be right for
Pancreatic Adenocarcinoma
ERYtech Pharma 512
Testing effectiveness (Phase 2)Looking for participantsNCT06562348
What this trial is testing

The ctDNA-RECIST Trial Part One

Who this might be right for
Gastrointestinal Neoplasm
Karen-Lise Garm Spindler 167
Early research (Phase 1)Looking for participantsNCT06240728
What this trial is testing

NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Who this might be right for
Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc. 144
Not applicableUnknownNCT06070623
What this trial is testing

Follow up After TACE by Elastography and Color Doppler.

Who this might be right for
Hepatocellular Carcinoma
Assiut University 54
Not applicableLooking for participantsNCT06142058
What this trial is testing

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

Who this might be right for
EvaluationNSCLCTargeted Therapy
Xueqin Yang 44
Testing effectiveness (Phase 2)Study completedNCT00558103
What this trial is testing

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 163
Not applicableUnknownNCT05254132
What this trial is testing

Artificial Intelligence for Help Non-Small Cell Lung Cancer: Measure Cancer Biology and Treatment Response Via Imaging

Who this might be right for
Non Small Cell Lung Cancer
OncoRadiomics 1,000
Not applicableStudy completedNCT04079283
What this trial is testing

Radiomics of Immunotherapeutics Response Evaluation and Prediction

Who this might be right for
Solid TumorPredictive Cancer Model
Tianjin Medical University Cancer Institute and Hospital 285
Testing effectiveness (Phase 2)Study completedNCT05455424
What this trial is testing

Niraparib Efficacy in Patient With Unresectable Mesothelioma

Who this might be right for
Mesothelioma, Malignant
University Hospital Southampton NHS Foundation Trust 88
Large-scale testing (Phase 3)Study completedNCT05061823
What this trial is testing

Bintrafusp Alfa Program Rollover Study

Who this might be right for
Lung CancerCancer
EMD Serono Research & Development Institute, Inc. 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT05000710
What this trial is testing

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Who this might be right for
Metastatic or Locally Advanced NSCLC
Sheba Medical Center 29
Testing effectiveness (Phase 2)UnknownNCT00290485
What this trial is testing

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Who this might be right for
Gastrointestinal Stromal Tumors
Maisonneuve-Rosemont Hospital 50
Not applicableStudy completedNCT04780789
What this trial is testing

Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization

Who this might be right for
Hepatocellular CarcinomaHepatocellular Carcinoma by BCLC Stage
Brno University Hospital 61
Testing effectiveness (Phase 2)Study completedNCT04133948
What this trial is testing

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Who this might be right for
Malignant Melanoma Stage III
The Netherlands Cancer Institute 44
Not applicableNot Yet RecruitingNCT07208526
What this trial is testing

Trial of Surgical Decision-Making Guided by TDTP-RECIST

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)Conversion TherapyTDTP-RECIST+1 more
Shanghai Zhongshan Hospital 270
Early research (Phase 1)Ended earlyNCT04349280
What this trial is testing

Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 25
Testing effectiveness (Phase 2)Study completedNCT01915589
What this trial is testing

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Who this might be right for
Carcinoma, Hepatocellular
Bayer 16
Testing effectiveness (Phase 2)UnknownNCT04024800
What this trial is testing

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
NuGenerex Immuno-Oncology 29
Next Page